Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Hormones
Published in: Hormones 1/2018

01-03-2018 | Review Article

Diabetes and lipid metabolism

Authors: Vasilios G. Athyros, Michael Doumas, Konstantinos P. Imprialos, Konstantinos Stavropoulos, Eleni Georgianou, Alexandra Katsimardou, Asterios Karagiannis

Published in: Hormones | Issue 1/2018

Login to get access

Abstract

The authors review the association between diabetes mellitus (DM) and aberrations of lipid metabolism related to DM, diabetic dyslipidemia (DD). DM is considered as a major health burden worldwide and one of the most important modifiable cardiovascular disease (CVD) risk factors. This applies to both the developed and the developing countries, especially the latter. While patients with type 1 DM, 10% of all DM cases, usually do not have dyslipidemia, DD is frequent among patients with type 2 DM (T2DM) (prevalence > 75%) and is mainly a mixed dyslipidemia [increase in triglycerides (TGs), low high-density lipoprotein cholesterol (HDL-C), and small-dense (atherogenic), low-density lipoprotein cholesterol (LDL-C) particles]. The components of DD, which is characterized by quantitative (mentioned above), qualitative, and kinetic abnormalities all contributing to CVD risk, are mostly related to insulin resistance. Statins, ezetimibe, and PCSK9 inhibitors can be used in monotherapy or consecutively in combinations if needed. Statins compose the main drug. For the residual CVD risk after statin treatment, the use of statin-fibrate combinations is indicated only in patients with mixed dyslipidemia. In conclusion, DD is a major health problem worldwide. It is a significant CVD risk factor and should be treated according to current guidelines. The means today exist to normalize all quantitative, qualitative, and kinetic aberrations of DD, thereby reducing CVD risk.
Literature
1.
Taskinen MR, Borén J (2015) New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis 239:483–495CrossRefPubMed
2.
Guariguata L, Whiting DR, Hambleton I et al (2014) Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103:137–149CrossRefPubMed
3.
Zimmet PZ, Magliano DJ, Herman WH et al (2014) Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol 2:56–64CrossRefPubMed
4.
Whiting DR, Guariguata L, Weil C et al (2011) 2011 IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94:311–321CrossRefPubMed
5.
Shaw JE, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87:4–14CrossRefPubMed
6.
Grundy SM, Benjamin IJ, Burke GL et al (1999) Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. AHA SCIENTIFIC STATEMENT. Circulation 100:1134–1146CrossRefPubMed
7.
No authors listed 1999 Diabetes mellitus: a major risk factor for cardiovascular disease. A joint editorial statement by the American Diabetes Association; the National Heart, Lung, and Blood Institute; the Juvenile Diabetes Foundation International; the National Institute of Diabetes and Digestive and Kidney Diseases; and the American Heart Association. Circulation 100:1132–1133
8.
9.
Turner RC, Millns H, Neil HA et al (1988) Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ 316:823–828CrossRef
10.
Farmer JA (2008) Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials. Curr Diab Rep 8:71–77CrossRefPubMed
11.
Bulut T, Demirel F, Metin A (2017) The prevalence of dyslipidemia and associated factors in children and adolescents with type 1 diabetes. J Pediatr Endocrinol Metab 30(2):181–187CrossRefPubMed
12.
13.
Chapman MJ, Ginsberg HN, Amarenco P et al (2011) Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 32:1345–1361CrossRefPubMedPubMedCentral
14.
Isomaa B, Almgren P, Tuomi T et al (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683–689CrossRefPubMed
15.
Dake AW, Sora ND (2016) Diabetic dyslipidemia review: an update on current concepts and management guidelines of diabetic dyslipidemia. Am J Med Sci 351:361–365CrossRefPubMed
16.
Center for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States. http://​www.​cdc.​gov/ diabetes/pubs/ statsreport14/national-diabetes-report-web.pdf; 2014 Accessed 20.9.17
17.
Geiss LS, Wang J, Cheng YJ et al. Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980–2012. JAMA 312: 1218–1226
18.
Forouhi NG, Merrick D, Goyder E (2006) Diabetes prevalence in England, 2001—estimates from an epidemiological model. Diabetic Med 23:189–197CrossRefPubMed
19.
Wild S, Roglic G, Green A et al (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047–1053CrossRefPubMed
20.
Arredondo A, De Icaza E (2011) The cost of diabetes in Latin America: evidence from Mexico. Value Health 14(Suppl 1):S85–S88CrossRefPubMed
21.
Gujral UP, Pradeepa R, Weber MB, Narayan KM, Mohan V (2013) Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations. Ann N Y Acad Sci 1281:51–63CrossRefPubMedPubMedCentral
22.
Mohan V (2004) Why are Indians more prone to diabetes. J Assoc Physicians India 52:468–474PubMed
23.
Williams GM, Long AE, Wilson IV et al (2016) Beta cell function and ongoing autoimmunity in long-standing, childhood onset type 1 diabetes. Diabetologia 59:2722–2726CrossRefPubMed
24.
Long AE, Gillespie KM, Rokni S, Bingley PJ, Williams AJ (2012) Rising incidence of type 1 diabetes is associated with altered immunophenotype at diagnosis. Diabetes 61:683–686CrossRefPubMedPubMedCentral
25.
26.
Taskinen MR (2003) Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46:733–749CrossRefPubMed
27.
Chahil TJ, Ginsberg HN, 2006 Diabetic dyslipidemia. Endocrinol Metab Clin North Am 35: 491–510, vii–viii
28.
Vergès B (2005) New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab 31:429–439CrossRefPubMed
29.
Doucet J, Le Floch JP, Bauduceau B, Verny C (2012) GERODIAB: glycaemic control and 5-year morbidity/mortality of type 2 diabetic patients aged 70 years and older: 1. Description of the population at inclusion. Diabetes Metab 38:523–530CrossRefPubMed
30.
Tziomalos K, Athyros VG, Karagiannis A, Kolovou GD, Mikhailidis DP (2009) Triglycerides and vascular risk: insights from epidemiological data and interventional studies. Curr Drug Targets 10:320–327CrossRefPubMed
31.
Wang J, Stancakova A, Soininen P et al (2012) Lipoprotein subclass profiles in individuals with varying degrees of glucose tolerance: a population-based study of 9399 Finnish men. J Intern Med 272:562–572CrossRefPubMed
32.
Arca M, Pigna G, Favoccia C (2012) Mechanisms of diabetic dyslipidemia: relevance for atherogenesis. Curr Vasc Pharmacol 10:684–686CrossRefPubMed
33.
Mikhailidis DP, Elisaf M, Rizzo M et al (2011) European panel on low density lipoprotein (LDL) subclasses: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol 9:531–532CrossRefPubMed
34.
Athyros VG, Alexandrides TK, Bilianou H et al (2017) The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An expert panel statement. Metabolism 71:17–32CrossRefPubMed
35.
36.
Xiao C, Lewis GF (2012) Regulation of chylomicron production in humans. Biochim Biophys Acta 1821:736–746CrossRefPubMed
37.
Veilleux A, Grenier E, Marceau P et al (2014) Intestinal lipid handling: evidence and implication of insulin signaling abnormalities in human obese subjects. Arterioscler Thromb Vasc Biol 34:644–653CrossRefPubMed
38.
Xiao C, Dash S, Morgantini C et al (2014) New and emerging regulators of intestinal lipoprotein secretion. Atherosclerosis 233:608–615CrossRefPubMed
39.
Axelsen M, Smith U, Eriksson JW, Taskinen MR, Jansson PA (1999) Postprandial hypertriglyceridemia and insulin resistance in normoglycemic first-degree relatives of patients with type 2 diabetes. Ann Intern Med 131:27–31CrossRefPubMed
40.
Borén J, Matikainen N, Adiels M, Taskinen MR (2014) Postprandial hypertriglyceridemia as a coronary risk factor. Clin Chim Acta 431:131–142CrossRefPubMed
41.
Fujioka Y, Ishikawa Y (2009) Remnant lipoproteins as strong key particles to atherogenesis. J Atheroscler Thromb 16:145–154CrossRefPubMed
42.
Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP (2015) Genetic, epidemiologic and clinical data strongly suggest that fasting or non-fasting triglycerides are independent cardiovascular risk factors. Curr Med Res Opin 31:435–438CrossRefPubMed
43.
Stefanutti C, Labbadia G, Athyros VG (2014) Hypertriglyceridaemia, postprandial lipaemia and non-HDL cholesterol. Curr Pharm Des 20:6238–6248CrossRefPubMed
44.
Grundy SM, Cleeman JI, Merz CN et al (2004) Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 110:227–239CrossRefPubMed
45.
Catapano AL, Reiner Z, De Backer G, European Society of Cardiology (ESC); European Atherosclerosis Society (EAS) et al (2011) ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217:3–46CrossRefPubMed
46.
Stock J (2012) News from the literature: focus on joint ESC/EAS dyslipidemia guidelines. Atherosclerosis 220:42–44CrossRefPubMed
47.
Khavandi M, Duarte F, Ginsberg HN, Reyes-Soffer G (2017) Treatment of dyslipidemias to prevent cardiovascular disease in patients with type 2 diabetes. Curr Cardiol Rep 19:7CrossRefPubMedPubMedCentral
48.
Stone NJ, Robinson JG, Lichtenstein AH, American College of Cardiology/American Heart Association Task Force on Practice Guidelines et al (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129(25 Suppl 2):S1–S45
49.
American Diabetes Association (2015) Cardiovascular disease and risk management. Diabetes Care 38(Supplement 1):S49–S57CrossRef
50.
Piepoli MF, Hoes AW, Agewall S (2016) European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 252:207–274CrossRefPubMed
51.
Jellinger PS, Handelsman Y, Rosenblit PD et al (2017) American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract 23(Suppl 2):1–87CrossRefPubMed
52.
American Diabetes Association (2017) Cardiovascular disease and risk management. Sec. 9. In Standards of Medical Care in Diabetes-2017. Diabetes Care 40:S75–S87CrossRef
53.
Cannon CP, Blazing MA, Giugliano RP, IMPROVE-IT Investigators et al (2015) Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372:2387–2389CrossRefPubMed
54.
Katsiki N, Athyros VG, Mikhailidis DP (2016) More news from IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial). Hormones (Athens) 15:5–7CrossRef
55.
Sabatine MS, Giugliano RP, Keech AC, FOURIER Steering Committee and Investigators et al (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376:1713–1722CrossRefPubMed
56.
Katsiki N, Athyros VG, Mikhailidis DP, Mantzoros C (2017) Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial. Metabolism 74:43–46CrossRefPubMed
57.
Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2017 Focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 70:1785–1822
58.
Ridker PM, Revkin J, Amarenco P, SPIRE Cardiovascular Outcome Investigators et al (2017) Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med 376:1527–1539CrossRefPubMed
59.
Fruchart JC, Sacks F, Hermans MP et al (2008) Residual Risk Reduction Initiative (R3I): The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res 5:319–335CrossRefPubMed
60.
61.
Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. Open Cardiovasc Med J 5:24–34
62.
Athyros VG, Doumas M, Karagiannis A (2016) Differential residual dyslipidemia/cardiovascular risk after statin treatment between Asian-Indians and western whites. Call for action. Indian Heart J 68:596–598CrossRefPubMedPubMedCentral
63.
Katsiki N, Koumaras C, Athyros VG, Karagiannis A (2012) Thinking beyond traditional cardiovascular risk factors: the role of arterial stiffness in targeting residual risk. Angiology 63:9–11CrossRefPubMed
64.
Athyros VG, Wierzbicki AS (2014) Statin-fibrate combination therapy is safe and effective in normalizing lipid profile and in keeping cardiovascular event rates low. Curr Med Res Opin 30:57–58CrossRefPubMed
65.
ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd (2010) Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362:1563–1574CrossRef
66.
Keech A, Simes RJ, Barter P, FIELD study investigators et al (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849–1861CrossRefPubMed
67.
Tenenbaum A, Medvedofsky D, Fisman EZ et al (2012) Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data. PLoS One 7:e35298CrossRefPubMedPubMedCentral
68.
Rubins HB, Robins SJ, Collins D et al (2002) Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 162:2597–2604CrossRefPubMed
69.
Sacks FM, Carey VJ, Fruchart JC (2010) Combination lipid therapy in type 2 diabetes. N Engl J Med 363:692–694CrossRefPubMed
70.
Tenenbaum A, Fisman EZ et al (2010) “If it ain’t broke, don’t fix it”: a commentary on the positive-negative results of the ACCORD lipid study. Cardiovasc Diabetol 9:24
71.
Wierzbicki AS, Mikhailidis DP, Wray R, Schacter M, Cramb R, Simpson WG, Byrne CB (2003) Statin-fibrate combination: therapy for hyperlipidemia: a review. Curr Med Res Opin 19(3):155–168CrossRefPubMed
72.
Athyros VG, Papageorgiou AA, Kontopoulos AG (2001) Statin-fibrate combinations in patients with combined hyperlipidemia. Atherosclerosis 155:263–264CrossRefPubMed
73.
Athyros VG, Papageorgiou AA, Athyrou VV et al (2002) Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia. J Cardiovasc Risk 9:33–39CrossRefPubMed
74.
Athyros VG, Papageorgiou AA, Hatzikonstandinou HA et al (1997) Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 80:608–613CrossRefPubMed
75.
Mitsiou EK, Athyros VG, Karagiannis A, Mikhailidis DI (2012) Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes? Open Cardiovasc Med J 6:28–32CrossRefPubMedPubMedCentral
76.
Czupryniak L, Joshi SR, Gogtay JA, Lopez M (2016) Effect of micronized fenofibrate on microvascular complications of type 2 diabetes: a systematic review. Expert Opin Pharmacother 17:1463–1473CrossRefPubMed
77.
78.
European Medicines Agency 2013 European medicines agency confirms recommendation to suspend Tredaptive, Pelzont and Trevaclyn. January 18, 201
79.
The HPS2-THRIVE Collaborative Group (2014) Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 371:203–212CrossRef
80.
Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP (2015) Nicotinic acid and new-onset diabetes. Horm Metab Res 47:544–545PubMed
81.
Packard C, Caslake M, Shepherd J (2000) The role of small, dense low density lipoprotein (LDL): a new look. Int J Cardiol 74:S17–S22CrossRefPubMed
82.
Rizzo M, Berneis K (2006) The clinical relevance of low-density-lipoproteins size modulation by statins. Cardiovasc Drugs Ther 20:205–217CrossRefPubMed
83.
Ip S, Lichtenstein AH, Chung M, Lau J, Balk EM (2009) Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes. Ann Intern Med 150:474–484CrossRefPubMed
84.
Gouni-Berthold I, Mikhailidis DP, Rizzo M (2012) Clinical benefits of ezetimibe use: is absence of proof, proof of absence? Expert Opin Pharmacother 13:1985–1988CrossRefPubMed
85.
Superko HR, Berneis KK, Williams PT, Rizzo M, Wood PD (2005) Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. Am J Cardiol 96:1266–1272CrossRefPubMed
86.
Simental-Mendía LE, Simental-Mendía M, Sánchez-García A et al (2017) Effect of fibrates on glycemic parameters: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res
87.
Sahebkar A, Watts GF (2013) Fibrate therapy and circulating adiponectin concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Atherosclerosis 230:110–120CrossRefPubMed
88.
Tsunoda T, Nozue T, Yamada M, Mizuguchi I, Sasaki M, Michishita I (2013) Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance. Diabetes Res Clin Pract 100:46–52CrossRefPubMed
89.
Flachs P, Rossmeisl M, Kopecky J (2014) The effect of n-3 fatty acids on glucose homeostasis and insulin sensitivity. Physiol Res 63:S93–S118
90.
Kostapanos MS, Liamis GL, Milionis HJ, Elisaf MS (2010) Do statins beneficially or adversely affect glucose homeostasis? Curr Vasc Pharmacol 8:612–631CrossRefPubMed
91.
Kostapanos MS, Agouridis AP, Elisaf MS (2015) Variable effects of statins on glucose homeostasis parameters and their diabetogenic role. Diabetologia 58:1960–1961CrossRefPubMed
Metadata
Title
Diabetes and lipid metabolism
Authors
Vasilios G. Athyros
Michael Doumas
Konstantinos P. Imprialos
Konstantinos Stavropoulos
Eleni Georgianou
Alexandra Katsimardou
Asterios Karagiannis
Publication date
01-03-2018
Publisher
Springer International Publishing
Published in
Hormones / Issue 1/2018
Print ISSN: 1109-3099
Electronic ISSN: 2520-8721
DOI
https://doi.org/10.1007/s42000-018-0014-8

Other articles of this Issue 1/2018

Hormones 1/2018 Go to the issue

Review Article

Imaging of nonalcoholic fatty liver disease and its clinical utility

Editorial

Hormones—International Journal of Endocrinology and Metabolism: a new publisher, a step forward

Review

The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data

Case Report

Two rare forms of congenital adrenal hyperplasia, 11β hydroxylase deficiency and 17-hydroxylase/17,20-lyase deficiency, presenting with novel mutations

Short Review

Perinatal SSRI medications and offspring hippocampal plasticity: interaction with maternal stress and sex

Original Article

Relationship of lipid regulatory gene polymorphisms and dyslipidemia in a pediatric population: the CASPIAN III study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits